Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy

Oncology

Volumn 71, Issue 5-6, 2007, Pages 312-319

  Giralt, Jordi ^a   Navalpotro, Begoña ^a   Hermosilla, Eduardo ^a   De Torres, Ines ^a   Espin, Eloi ^a   Reyes, Victoria ^a   Cerezo, Laura ^b   De Las Heras, Manuel ^c   Ramon Y Cajal, Santiago ^a   Armengol, Manel ^a   Benavente, Sergi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cyclooxygenase 2; Radiotherapy; Rectal cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CYCLOOXYGENASE 2; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOPSY TECHNIQUE; CALCULATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECTUM CANCER; REGRESSION ANALYSIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35348851655     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107105     Document Type: Article

References (28)

1. Crane CH, Skibber JM, Feig BW, et al: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003;97:517-524.
2. Sauer R, Becker H, Hohenberger W, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
3. Fosslien E: Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
4. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
5. Tomozawa S, Tsuno NH, Sunami E, et al: COX-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis of colorectal cancer. Br J Cancer 2000;83:324-328.
6. Madaan S, Abel PD, Chaudhari KS, et al: Cytoplasmic induction and overexpression of COX-2 in human prostate cancer: implications for prevention and treatment. Br J Urol 2000;86:736-741.
7. Hwang D, Skollard D, Byrne J, Levine E: Expression of cyclooxygenase 1 and cylooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460.
8. Achiwa H, Yatabe Y, Hida T, et al: Prognostic significance of elevated COX-2 expression in primary resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-1005.
9. Sheehan KM, Sheahan K, O'Donoghue DP, et al: The relationship between COX-2 expression and colorectal cancer. JAMA 1999;282:1254-1257.
10. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
11. Ferrara N, Gerber HP, Le Couter J: The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
12. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543.
13. Adams J, Carder PJ, Downey S, et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898-2905.
14. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 2000;18:2046-2052.
15. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088-3095.
16. Lee JC, Chow NH, Wang ST, et al: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753.
17. Zlobec I, Steele R, Compton CC: VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005;104:2517-2521.
18. Yoshimura H, Dhar DK, Cono H, et al: Prognostic impact of hypoxia-inducible factors 1 and 2 in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004;10:8554-8560.
19. Giralt J, de las Heras M, Cerezo L, et al: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101-108.
20. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
21. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
22. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
23. Jung YD, Nakano K, Liu W, Gallick GE, Ellis LM: Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 1999;59:4804-4807.
24. Cassano A, Bagala C, Battelli C, et al: Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002;22:2179-2184.
25. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W: COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22:1225-1230.
26. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P: Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760.
27. Pachkoria I, Zhang H, Adell G, Jarlsfelt I, Sun XF: Significance of COX-2 expression in rectal cancers with or without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:739-744.
28. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471.